about
Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trialsSuvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled TrialsMemantine monotherapy for Alzheimer's disease: a systematic review and meta-analysisEmerging roles of ARHGAP33 in intracellular trafficking of TrkB and pathophysiology of neuropsychiatric disorders.Novel rare variants in F-box protein 45 (FBXO45) in schizophrenia.Replication and cross-phenotype study based upon schizophrenia GWASs data in the Japanese population: support for association of MHC region with psychosis.Oxytocin receptor gene variations predict neural and behavioral response to oxytocin in autism.Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia.Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population.De novo non-synonymous TBL1XR1 mutation alters Wnt signaling activity.Voxel-based morphometric brain comparison between healthy subjects and major depressive disorder patients in Japanese with the s/s genotype of 5-HTTLPR.Our explain to three doubtsSerum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients.The polymorphism of YWHAE, a gene encoding 14-3-3epsilon, and brain morphology in schizophrenia: a voxel-based morphometric studyEfficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Excess of homozygosity in the major histocompatibility complex in schizophrenia.Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis.Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Resequencing and association analysis of PTPRA, a possible susceptibility gene for schizophrenia and autism spectrum disorders.Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan.High-resolution copy number variation analysis of schizophrenia in Japan.A population-specific uncommon variant in GRIN3A associated with schizophrenia.Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials.A genetic variant in 12q13, a possible risk factor for bipolar disorder, is associated with depressive state, accounting for stressful life eventsSelective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.Genetic variants on 3q21 and in the Sp8 transcription factor gene (SP8) as susceptibility loci for psychotic disorders: a genetic association study.Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophreniaCardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials.Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysisVarenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis.Identification of Rare, Single-Nucleotide Mutations in NDE1 and Their Contributions to Schizophrenia Susceptibility.Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramineProtection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled TrialsGlutamate Networks Implicate Cognitive Impairments in Schizophrenia: Genome-Wide Association Studies of 52 Cognitive PhenotypesEfficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.Histamine H3 Receptor Antagonists for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.Memantine for the treatment of frontotemporal dementia: a meta-analysis.
P50
Q26781173-98DC49C6-9E0A-4C53-8D44-754FF221EC00Q26796379-109923F8-A011-4AEE-A7C7-323D98F9262EQ26861399-E610FAFF-5855-4D3E-A197-52F2BD9E8BA3Q27333743-EED101D0-96E8-482B-8E23-50751D88167AQ30363038-16F4332C-21B1-4852-9CFC-66A6B30DBFE8Q30828357-190E134C-17BB-486F-9675-BD182BDC0327Q30845236-4A59C196-E719-4BDD-A2BD-88D0F2103027Q33662909-4E919AC7-A4D2-4B7A-84C9-240B5F481095Q33713759-41D451C3-3257-4095-8F62-128F5CB3F112Q33767203-2E2790A7-0A1F-471C-9C4C-71C3FD297FBAQ33822592-8F9369A6-D901-4102-96CA-B335EF41E81CQ33858243-98B4936C-B7DF-4922-A7AE-DA99A37934DAQ33986157-4D9B726E-0FD8-403C-A6D8-8CEFD87C8B9EQ34020393-CFC3F3A6-9589-457E-9B12-DBC80B42EAB7Q34354401-48972C92-DBC5-4488-AB1B-D8CDC3B0F18DQ34379000-092735ED-42B0-451A-83AF-0C527738EDB1Q34386886-997A59A2-60A1-4CE4-B887-E3CC9E9C4252Q34432085-FBC873F8-03A4-481F-9D4D-4CDD7FBB3211Q34506299-01477DEE-350D-41FE-B765-9CA95D8CF21DQ34523396-199697E1-B521-4359-B5C4-C94832EDD04AQ34528802-0D524C04-737C-4354-BD2A-830B7739F419Q34646384-DD53C9A9-59D0-453E-8643-345CD1443496Q34646717-7939A7E5-94DA-4771-A107-1DB85F31601DQ34678198-9C1D0A67-05A0-4AA5-BAE2-EE3D97423972Q34724364-B5EB6E6C-6D53-4502-A861-074453FA2F7FQ34879435-67BCAD15-D7DF-4801-91CD-1FA67597A80EQ34963267-E08F5A6D-5C2F-45F4-B47F-4A1C95597488Q35007214-56778FCC-A63B-4C82-9DA4-97A1657AA4BEQ35088447-512928C1-85BA-4A10-B1A5-64A8F4F6828FQ35136085-03677775-AE33-4D13-8020-B5677AD24FC5Q35224262-10396056-F924-4A6C-99BE-379F43233BB7Q35224319-8B73ACF1-40D3-40D0-87B7-52C4F4F50B15Q35302795-CFB886A5-DC12-4B64-9688-87ECCF1714A3Q35369750-E7061372-0FFA-4C47-A616-71B411A9A1C2Q35530626-B1A3DA74-DF46-4ADF-B02A-BB9B8F2FE7A5Q35669030-69C70BB5-E8D7-4158-81DB-F1BD4FFC1AB9Q35739000-FD2B1477-CBA3-44A3-AB6D-7524BC36B672Q35754102-F9A744F4-36D1-4D2B-B087-FC528F8DBECCQ35786464-7567B414-A8D4-4189-973F-38D86779CA4EQ35863915-55A0F5DA-81AD-4B72-A0A5-1AAACC5B9D41
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Nakao Iwata
@en
Nakao Iwata
@nl
type
label
Nakao Iwata
@en
Nakao Iwata
@nl
prefLabel
Nakao Iwata
@en
Nakao Iwata
@nl
P108
P31
P496
0000-0003-3189-6076